Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11088706 | 0.87 | PARP1 (0.66) | PARP1LMNAHTR6SGMS2RXFP1 | |
| SCHEMBL12420601 | 0.81 | NR4A2 (0.62) | PARP1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL12420766 | 0.80 | NR4A2 (0.62) | PARP1LMNAALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2195211 | 0.80 | NR4A2 (0.60) | PARP1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2453382 | 0.78 | LMNA (0.62) | LMNASGMS2MAPTHPGDALDH1A1 | |
| SCHEMBL5506154 | 0.78 | PARP1 (1.00) | PARP1LMNA | |
| SCHEMBL12420848 | 0.77 | NR4A2 (0.47) | PARP1HTR6 | |
| SCHEMBL12508515 | 0.77 | SGMS2 (0.72) | LMNASGMS2 | |
| SCHEMBL12420762 | 0.76 | NR4A2 (0.55) | — | |
| SCHEMBL1578425 | 0.75 | KMT2A (0.68) | LMNAMAPTHPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | PARP1 3006/4885LMNA 4308/4885HTR6 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.